Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function

P B Jeppesen, P Lund, I B Gottschalck, H B Nielsen, J J Holst, J Mortensen, S S Poulsen, B Quistorff, P B Mortensen, P B Jeppesen, P Lund, I B Gottschalck, H B Nielsen, J J Holst, J Mortensen, S S Poulsen, B Quistorff, P B Mortensen

Abstract

Background and aims: In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years.

Methods: GLP-2, 400 micrograms, s.c.,TID, were offered, to eleven SBS patients keeping parenteral support constant. 72-hour nutritional balance studies were performed at baseline, weeks 13, 26, 52 during two years intermitted by an 8-week washout period. In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR, lungfunction, exercise test) were measured.

Results: GLP-2 compliance was >93%. Three of eleven patients did not complete the study. In the remaining 8 patients, GLP-2 significantly reduced the fecal wet weight from approximately 3.0 to approximately 2.0 kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and urinary weight constant. Renal function improved. No significant changes were demonstrated in energy intake or absorption, and GLP-2 did not significantly affect mucosal morphology, body composition, bone mineral density or muscle function.

Conclusions: GLP-2 treatment reduces fecal weight by approximately 1000 g/d and enables SBS patients to maintain their intestinal fluid and electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.

References

    1. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467–1475.
    1. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. Journal of Clinical Endocrinology and Metabolism. 1999;84(7):2513–2517.
    1. Bozkurt A, Naslund E, Holst JJ, Hellstrom PM. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regulatory Peptides. 2002;107(1–3):129–135.
    1. Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scandinavian Journal of Gastroenterology. 1998;33:828–832.
    1. Guan X, Stoll B, Lu X, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets. Gastroenterology. 2003;125(1):136–147.
    1. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(15):7911–7916.
    1. Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. American Journal of Physiology. 1997;273(6):G1252–G1262.
    1. Litvak DA, Hellmich MR, Evers BM, Banker NA, Townsend CM., Jr. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. Journal of Gastrointestinal Surgery. 1998;2(2):146–150.
    1. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regulatory Peptides. 2005;124(1–3):105–112.
    1. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. American Journal of Physiology. 1997;272(6):E1050–E1058.
    1. Cheeseman CI, O'Neill D. Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2. Experimental Physiology. 1998;83(5):605–616.
    1. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP- 2 infusion in vivo. American Journal of Physiology. 1997;273(6):R1965–R1971.
    1. Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women. Bone. 2007;40(3):723–729.
    1. Pironi L, Zolezzi C, Ruggeri E, Paganelli F, Pizzoferrato A, Miglioli M. Bone turnover in short-term and long-term home parenteral nutrition for benign disease. Nutrition. 2000;16(4):272–277.
    1. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4):806–815.
    1. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant qlucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224–1231.
    1. Haderslev KV, Jeppesen PB, Hartmann B, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scandinavian Journal of Gastroenterology. 2002;37(4):392–398.
    1. Schmassmann A, Fehr HF, Locher J, et al. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology. 1993;104(4):1171–1181.
    1. Schmassmann A, Angellotti MA, Ton-Nu HT, et al. Transport, metabolism, and effect of chronic feeding of cholylsarcosine, a conjugated bile acid resistant to deconjugation and dehydroxylation. Gastroenterology. 1990;98(1):163–174.
    1. Heydorn S, Jeppesen PB, Mortensen PB. Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome. Scandinavian Journal of Gastroenterology. 1999;34(8):818–823.
    1. Jeppesen PB, Mortensen PB. Colonic digestion and absorption of energy from carbohydrates and medium-chain fat in small bowel failure. Journal of Parenteral and Enteral Nutrition. 1999;23(5, supplement):S101–S105.
    1. Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut. 1998;43(6):763–769.
    1. Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clinical Chemistry. 1998;44(11):2281–2289.
    1. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. The European Respiratory Journal. 1993;16:41–52.
    1. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. The European Respiratory Journal. 1993;16:5–40.
    1. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. American Review of Respiratory Disease. 1969;99(5):696–702.
    1. Ratkevicius A, Quistorff B. Metabolic costs of force generation for constant-frequency and catchlike-inducing electrical stimulation in human tibialis anterior muscle. Muscle and Nerve. 2002;25(3):419–426.
    1. Johansen L, Quistorff B. 31P-MRS characterization of sprint and endurance trained athletes. International Journal of Sports Medicine. 2003;24(3):183–189.
    1. Nakagawa Y, Ratkevicius A, Mizuno M, Quistorff B. ATP economy of force maintenance in human tibialis anterior muscle. Medicine and Science in Sports and Exercise. 2005;37(6):937–943.
    1. Galbo H, Kjaer M, Secher NH. Cardiovascular, ventilatory and catecholamine responses to maximal dynamic exercise in partially curarized man. Journal of Physiology. 1987;389:557–568.
    1. Bogert LWJ, van Lieshout JJ. Non-invasive pulsatile arterial pressure and stroke volume changes from the human finger. Experimental Physiology. 2005;90(4):437–446.
    1. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with Glucagon-Like Peptide 2 (GLP-2): compliance, safety and effects on quality of life. Gastroenterology Research and Practice. 2009;2009
    1. Mizuno M, Horn A, Secher NH, Quistorff B. Exercise-induced 31P-NMR metabolic response of human wrist flexor muscles during partial neuromuscular blockade. American Journal of Physiology. 1994;267(2, part 2):R408–R414.
    1. Friedman HI, Chandler JG, Peck CC, Nemeth TJ, Odum SK. Alterations in intestinal structure, fat absorption and body weight after intestinal bypass for morbid obesity. Surgery Gynecology and Obstetrics. 1978;146(5):757–767.
    1. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut. 1971;12(10):773–782.
    1. Stevens FM, Flanagan RW, O'Gorman D, Buchanan KD. Glucagonoma syndrome demonstrating giant duodenal villi. Gut. 1984;25(7):784–791.
    1. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004;53(8):1145–1150.
    1. Sylvan A, Sjolund B, Janunger KG, Rutegard J, Stenling R, Roos G. Colorectal cancer risk after jejunoileal bypass: dysplasia and DNA content in longtime follow-up of patients operated on for morbid obesity. Diseases of the Colon and Rectum. 1992;35(3):245–248.
    1. Lauverjat M, Aissa AH, Vanhems P, Bouletreau P, Fouque D, Chambrier C. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clinical Nutrition. 2006;25(1):75–81.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren